The international team achieved it by discovering the rules behind a type of protein structures that are essential for the interaction between proteins and small molecules
IRB Barcelona researcher, Enrique Marcos, is the first author of the study published today in Science
Scientists at the Institute for Research in Biomedicine (IRB Barcelona) and the KTH Royal Institute of Technology in Stockholm develop a new method that predicts the way in which proteins move to exert their biological functions.
They have demonstrated that protein movement is governed by the general shape of these molecules, thereby providing new data on how proteins work—a key step for drug development.
Eva Novoa was one of the first students to complete a PhD in as part of the ”la Caixa”/IRB Barcelona International PhD Programme in Biomedicine. She was a PhD student at IRB Barcelona between 2008 and 2012. Six months ago, she moved to Sydney, Australia to join the Garvan Institute of Medical Research as a Senior Research Officer. She just received the Young Research Award from the Catalan Society for Biology.
The Barcelona International Youth Science Challenge (BIYSC) is a singular programme run by the Catalunya-La Pedrera Foundation that seeks to bring together students with a passion for science and the best scientists in prestigious research centres in Catalonia.
IRB Barcelona participates in the BIYSC through the project “From DNA to protein related diseases”, which includes sessions about the different fields addressed at the institute.
Several media have picked up on the launch of the new biotechnology company Nostrum BioDiscovery, a joint initiative between IRB Barcelona and the Barcelona Supercomputing Center-National Supercomputing Center (BSC-CNS). Modesto Orozco, group leader of the Molecular Modelling and Bioinformatics lab at IRB Barcelona, will chair the new spin-off, which aims to launch new drugs and biotech molecules developed using computational simulation.
Nostrum BioDiscovery has come about from the combined efforts of IRB Barcelona and the BSC-CNS—two research centres of excellence in Barcelona—with the participation of the University of Barcelona and ICREA and supported by the Botín Foundation’s technology transfer programme.
The company boasts cutting-edge bioinformatics technologies to speed up the development and lower the cost of designing drugs—which are becoming increasingly more complex and expensive—and to further precision medicine.
Fierce BiotechIT, a biotechnology-specialized website, has written an article on the new European project, led by Modesto Orozco, which will inject 3€ million euros into 3-D genomics.
IRB Barcelona is to coordinate a Horizon2020 bioinformatics project that seeks to lay the groundwork for the emerging field of 3D genomics.
3D genomics provides information about the structures adopted by folded DNA inside a cell and about how they change over time and in response to alterations in cell environment. Modesto Orozco, the coordinator of the project says, “The 3D perspective will allow us to better relate changes in the genome with the corresponding diseases, because although 1D information is relevant, it falls short.”
Over three years, the project aims to provide a set of methods and integrated databases that can be used to store and process the data deriving from studies devoted to 3D genomics.
The European consortium comprises six international leading centres in method development and visualisation in 3D genomics.
Various media channels have commented on the launch of a DNA simulation tool developed by Modesto Orozco’s lab at IRB Barcelona, in collaboration with several international labs.
Published in Nature Methods, the work is available on an open-access basis through http://mmb.irbbarcelona.org/ParmBSC1/